Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company.Johnson & Johnson (JNJ -0.25%) is focusing on the next iteration of its business -- one that investors hope creates a lot more growth than in years past. The company spun off its consumer health business last year, and with just two main segments moving forward -- medical devices and innovative medicines -- J&J could be in a good position to accelerate its growth rate.But investors don't ap ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $147.19, denoting a -1.29% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.09%. Meanwhile, the Dow experienced a drop of 0.1%, and the technology-dominated Nasdaq saw an increase of 0.16%.Prior to today's trading, shares of the world's biggest maker of health care products had gained 1.46% over the past month. This has lagged the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.The ...

J&J is the textbook blue chip stock -- but it's not for everyone.Investing comes in many flavors, so there isn't a right or wrong approach: You should do what's best for you. That applies even to dividend investing. For some, dividend investing means maximizing immediate income, even if it requires sacrificing some growth and long-term upside; for others, it's the opposite.Healthcare juggernaut Johnson & Johnson (JNJ 0.25%) is a hallowed name in the dividend community, both for its brand recognition and for ...

blackred FOMO (fear of missing out) is hard to ignore when it comes to buying stocks in today's market, especially when influencers post headline-making comments about meme stocks like GameStop (GME) or when expensive stocks just keep going up, as in the case of Nvidia (NVDA), whose market cap just surpassed that of Microsoft (MSFT) to become the world's most valuable company. I'm not bothered, however, by not participating in the aforementioned stock rallies as I'm happy to layer into discounted divide ...

Johnson & Johnson (JNJ) announced that it has submitted a supplemental biologics license application (sBLA) seeking approval of its immunology drug, Tremfya, for a new indication — moderately to severely active Crohn’s disease (CD). This marks the second label expansion filing for Tremfya in three months, following the sBLA in active ulcerative colitis (UC) indication that was filed in March.Tremfya is currently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in sever ...

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programsTREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn's diseaseGALAXI includes data demonstrating superior outcomes for TREMFYA® versus STELARA® (ustekinumab) in Crohn's diseaseSPRING HOUSE, Pa., June 20, 2 ...

Key Findings from the GRAVITI Study - The Phase 3 GRAVITI study of TREMFYA® (guselkumab) achieved all primary and secondary endpoints, demonstrating statistically significant and clinically meaningful outcomes for clinical remission and endoscopic response at Week 12 in adult patients with moderately to severely active Crohn's disease [1] - The study also showed significant results for secondary endpoints at Weeks 24 and 48 compared to placebo, reinforcing the potential of TREMFYA® as a treatment option for Crohn's disease [1] - TREMFYA® is positioned to be the only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, providing versatility for patients and healthcare providers [1] About the GRAVITI and GALAXI Programs - The GRAVITI program is a randomized, double-blind, placebo-controlled Phase 3 study evaluating guselkumab SC induction therapy (400 mg at Weeks 0, 4, and 8) in patients with Crohn's disease who had inadequate response to conventional or biologic therapies [3] - The GALAXI program includes Phase 2 and Phase 3 studies (GALAXI 1, 2, and 3) designed to evaluate the efficacy and safety of guselkumab in Crohn's disease patients, with long-term extension studies assessing outcomes over five years [4] About Crohn's Disease - Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract affecting approximately 3 million Americans and 4 million Europeans, with symptoms including abdominal pain, diarrhea, and weight loss [5][6] - The disease has no known cure and is associated with immune system abnormalities potentially triggered by genetic, dietary, or environmental factors [5][6] About TREMFYA® (guselkumab) - TREMFYA® is a fully-human, dual-acting monoclonal antibody that blocks IL-23 by binding to its p19 subunit and CD64, a receptor on IL-23-producing cells [7] - It is approved in multiple countries for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis, with ongoing studies for ulcerative colitis and Crohn's disease [7] About STELARA® (ustekinumab) - STELARA® is an IL-12 and IL-23 antagonist approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in the United States [13] - It is marketed exclusively by the Janssen Pharmaceutical Companies of Johnson & Johnson [13] About Johnson & Johnson - Johnson & Johnson focuses on healthcare innovation, aiming to prevent, treat, and cure complex diseases through its expertise in Innovative Medicine and MedTech [25] - The company is committed to delivering personalized healthcare solutions and driving breakthroughs in the industry [25]

Loading...Loading...As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.Mega-cap stocks, known for their large market capitalizations and relatively stable performances, are often considered safe havens during uncertain times. However, even within this category, there are bargains to be found. Moreover, even in times wh ...

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatmentsVIENNA, June 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa scor ...

24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 studyMADRID, June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable ...